Quarterly report pursuant to Section 13 or 15(d)

Supplemental Disclosure for Statement of Cash Flows (Details)

v3.23.3
Supplemental Disclosure for Statement of Cash Flows (Details) - USD ($)
$ in Thousands
3 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Jul. 31, 2023
Supplemental Disclosure for Statement of Cash Flows (Details) [Line Items]      
Interest paid  
Cash flows from operating activities (13,374) (8,693)  
Escrowed proceeds were included in prepaid and other assets   $ 5,000
Restricted cash collateral deposit 1,000  
Tax on capital paid 467    
Prepaid and Other Assets [Member]      
Supplemental Disclosure for Statement of Cash Flows (Details) [Line Items]      
Escrowed proceeds were included in prepaid and other assets 5,000    
Enzo Clinical Labs [Member]      
Supplemental Disclosure for Statement of Cash Flows (Details) [Line Items]      
Restricted cash collateral deposit 1,000    
Right of Use Assets and Liabilities [Member]      
Supplemental Disclosure for Statement of Cash Flows (Details) [Line Items]      
Cash flows from operating activities $ 148 $ 1